Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (302)	10/4/2005 6:35:19 PM
From: NeuroInvestment	Respond to of 362

Well, Richard Allen was the founder of Theracell, and developed the Spheramine platform which was subsequently acquired by Titan. Perhaps he knows something from Schering's trials, but it is also possible that his objectivity about Spheramine might not be 100%--how many of us are objective about our own creations? Harry NeuroInvestment

To: Icebrg who wrote (302)	10/10/2005 2:36:34 PM
From: Icebrg	Read Replies (3) \| Respond to of 362

More insider activity. CEO and Chairman Louis Bucalo (that snake) has filed for an outright share buy of 62.000 shares. He got them cheap @ 1,70. The market doesn't value the company's chances very positively at the moment - market cap is at 59 mUSD. But Allen and Bucalo seem to be of a different opinion. After Bucalo's transaction he holds close to 500.000 shares. So, there was really no reason to buy more, me thinks. What is he up to? Erik PS. The market seems to have noticed.